Patent ID: 8318190

Claim:
A method of treating an immune-mediated or proliferative disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising zotarolimus, or a salt or prodrug thereof, and paclitaxel, or a salt or prodrug thereof; wherein the prodrug of paclitaxel is an ester formed from paclitaxel and a group selected from the group consisting of acetyl, proprionyl, pivaloyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, methoxymethyl, indanyl, naturally or unnaturally-occurring amino acids; and wherein the prodrug of zotarolimus is an ester formed from zotarolimus and a group selected from the group consisting of acetyl, proprionyl, pivaloyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, methoxymethyl, indanyl, and naturally or unnaturally-occurring amino acids; or is of the following formula: wherein R═R 1 C(O)R 2 R 3 or R 1 C(S)R 2 R 3 where R 1 ═O or S; R 2 =nothing, O, N, S, alkyl, alkenyl, alkynyl, heterocycles, or aryl; R 3 =nothing, alkyl, alkenyl, alkynyl, heterocycles, or aryl, wherein alkyl, alkenyl, alkynyl, heterocycles, aryl groups are substituted or unsubstituted; wherein the ratio, r, of zotarolimus:paclitaxel by weight is 10:7≦r≦10:0.1, and wherein the loading of zotarolimus ranges from about 1 μg/mm to about 100 μg/mm of the stent and the loading of paclitaxel is 1 μg/mm of the stent.